| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $2.9M | — | +47.5% |
| SG&A Expense | $2.3M | — | +10.4% |
| Operating Income | -$5.3M | — | -28.2% |
| Net Income | -$5.1M | — | -22.5% |
| EPS (Basic) | -$0.98 | — | -40.0% |
| EPS (Diluted) | -$0.98 | — | -40.0% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $25.0M | +42.4% | +24.7% |
| Current Assets | $26.0M | +25.8% | +29.2% |
| Total Assets | $26.8M | +24.4% | +26.3% |
| Current Liabilities | $1.6M | -27.7% | -75.9% |
| Total Liabilities | $1.9M | -25.5% | -73.5% |
| Stockholders' Equity |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$3.0M | — | +15.5% |
| Financing Cash Flow | $10.5M | — | +4440.4% |
| $24.9M |
| +31.1% |
| +77.2% |